Command Palette

Search for a command to run...

Clinical Trials · NCT00311766

A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

TerminatedPhase 2TB-500 (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
RegeneRx Biopharmaceuticals, Inc.
Enrollment
30
Start date
Feb 2006
Locations
See registry
Primary endpoint
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
View TB-500 compound reference